

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-12150A	Serial No. 10/1013,084
	Applicants Macklin Brian Arnold et al	
	Filing Date 7/3/2003	Group 1626

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
JLC	AA	US 3,043,868	07-10-1962	Mundelein	
	AB	US 3,729,475	04-24-1973	Williamson et al	
	AC	US 3,824,249	07-16-1974	Regnier et al	
	AD	US 4,010,279	03-01-1977	Griss et al	
	AE	US 4,465,509	08-14-1984	Takematsu et al	
	AF	US 5,420,158	05-30-1995	Yous et al	
	AG	US 5,441,984	08-15-1995	Heath, Jr. et al	
JLC	AH	US 6,174,922	01-16-2001	Arnold et al	
	AI	US			
	AJ	US			
	AK	US			
	AL	US			
	AM	US			
	AN	US			
	AO	US			
	AP	US			
	AQ	US			
	AR				

Examiner Signature	<i>Pat A. G...</i>	Date Considered	9/17/04
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-12150A	Serial No. 10/613,684
	Applicants Macklin Brian Arnold et al	
	Filing Date 7/3/2003	Group 16210

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number 4-Kind Code <sup>5</sup> (if known)				
JAL	BA	DE-1238455	04-13-1967	Troponwerke Dinklage & Co.		
	BB	DE-2329037	12-19-1974	BASF, AG		
	BC	EP-0591057	10-01-1993	Adir et Compagnie		
	BD	EP-0757982	08-07-1996	Rousell UCLAF		
	BE	EP-0810220	05-01-1997	Pfizer, Inc.		
	BF	EP-0816309	06-11-1997	Eli Lilly and Company		
	BG	EP-0825164	06-11-1997	Eli Lilly and Company		
	BH	GB-933,168	09-08-1961	Smith, Kline and French Laboratories		
	BI	GB-2,181,728	10-21-1985	Indian Drugs and Pharmaceutical s		
	BJ	WO-96/10559	09-29-1995	Fujisawa Pharmaceutical Company Limited		
JAL	BK	WO-98/33496	01-30-1998	Eli Lilly and Company		
	BL					
	BM					
	BN					
	BO					
	BP					

Examiner Signature	<i>David L. Cope</i>	Date Considered	9/17/04
-----------------------	----------------------	--------------------	---------

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-12150A	Serial No. 10/613,684
	Applicants Macklin Brian Arnold et al	
	Filing Date 7/3/2003	Group 1026

	BQ					
	BR					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
JLC	CA	Chemical Abstracts, Vol. 86, No. 23, 6 June 1977, Abstract No. 171375, Adzhibekyan et al; C-arylcycloalkyl- and N-arylcycloalkyl-substituted barbituric acids, XP002118971 & Arm. Khim. Zh. 1976, 29(11), 952-958.	
	CB	Trivedi B. K., et al; Inhibitors of Acyl-CoA: cholesterol acyltransferase.4. A novel series of urea acat inhibitors as potential hypocholesterolemic agents, Journal of Med Chem, Vol 36, No. 22, 1 Jan 1993, 3300-3307	
	CC	Database CAPLUS on STN (Columbus, OH, USA), No. 96:20442, Solid-phase synthesis of larger peptides by a new strategy of detachment from the resin, Abstract, Niu et al., 18 January 1982, 20(9), 1833-1834	
	CD	Database CAPLUS on STN (Columbus, OH, USA), No. 129:161416, Preparation of sulfonamides as glutamate receptor potentiators, Abstract, Arnold et al, 05 October 1998	
JLC	CE	Database CAPLUS on STN (Columbus, OH, USA), No. 130:125067, Preparation of heterocyclic moiety-containing sulfonamide compounds as hypoglycemics, Abstract, Kayakiri et al., 1999	
JLC	CF	CA 137:47448, Larsen et al 2002	
	CG		
	CH		
	CI		
	CJ		
	CK		
	CL		
Examiner Signature JLC	Date Considered 9/17/04		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.